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endocytosis of ferritin have been found in neoplastic cells, [ 11 ] 
and were associated with membrane-specifi c transferrin recep-
tors (TfR) that are highly expressed in many cancers [ 12 ] including 
breast and brain cancer cells. [ 12,13 ] The unique architecture of 
AFt provides two interfaces: the outer surface of AFt can be 
modifi ed chemically or genetically with functional motifs [ 14 ] and 
the internal cavity can be used to encapsulate pharmaceutical 
agents such as anticancer drugs, magnetic resonance imaging 
(MRI), and fl uorescent imaging agents. [ 6,9,15,16 ] Recently, selec-
tive targeting and cargo delivery with heavy chain apoferritin 
(H-AFt) was demonstrated both in vitro [ 17 ] and in vivo. [ 18 ] 
 Gefi tinib (“Iressa,” ZD1839) is an orally active, epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitor. [ 19 ] This 
receptor family comprises four homologous receptors: EGFR 
(ErbB1/HER1), HER2 (ErbB2), HER3 (ErbB3), and HER4 
(ErbB4), which have an extracellular ligand binding domain, a 
single hydrophobic trans-membrane domain and a cytoplasmic 
tyrosine kinase domain. These receptors are activated by either 
homo- or heterodimerization upon ligand binding resulting in 
phosphorylation of specifi c tyrosine residues. [ 20,21 ] The over-
expression of EGFR and HER2 in breast cancer, is associated 
with poor prognoses. [ 20,22,23 ] Gefi tinib is used for treatment of 
EGFR and HER2 overexpressing breast cancers. [ 24,25 ] However, 
the therapeutic window of this drug is drastically narrowed by 
poor bioavailability, acquired resistance due to insuffi cient or 
ineffective cellular uptake and systemic toxicity resulting from 
interactions between drug and healthy tissue. [ 19,26 ] Also, orally 
administered Gefi tinib is taken up extensively by human serum 
albumin and hence other delivery systems such as liposomes 
have been investigated. [ 27 ] Development of a selective targeted 
delivery system would improve effi ciency of Gefi tinib treatment. 
 Herein, we report the use of human H-AFt as a delivery 
cage for Gefi tinib to improve drug selectivity for HER2 
overexpressing cells. The H-AFt-encapsulated-Gefi tinib 
(H-AFt/Gefi tinib) nanocomposite has potent and enhanced anti-
tumor activity against the HER2 overexpressing SKBR3 breast 
cancer cell line (GI 50 = 0.52 × 10 −6 M ) compared to Gefi tinib 
alone (GI 50 = 1.66 × 10 −6 M ;  Table  1 ). Enhanced drug effi cacy 
is achieved through sustained controlled drug release from the 
H-AFt cavity. In contrast, H-AFt-encapsulated-Gefi tinib treat-
ment of MDA-MB-231 breast cancer cell line, which does not 
express HER2, has shown decreased uptake of Gefi tinib com-
pared to treatment with unencapsulated drug. These results 
expose prospects for utilization of H-AFt as a carrier for targeted 
delivery of anticancer drugs to HER2 overexpressing tumors. 
 For effi cient entrapment of any drug into a delivery system, 
consideration of physical properties of both the drug and 
delivery system is important. Gefi tinib is a hydrophobic 
drug and H-AFt has six hydrophobic channels allowing the 
drug molecules to enter the H-AFt cavity by passive diffusion 
 Development of a tumor-specifi c drug delivery system is chal-
lenging and depends immensely on the carrier. Currently 
various approaches are considered to develop effi cient drug 
delivery systems. [ 1,2 ] Leaky vasculature, associated with sus-
tained tumor angiogenesis together with tumor-associated poor 
lymphatic drainage can enhance passive targeting of nano-
particles (NPs) to malignant tissue resulting in the enhanced 
permeability retention effect. [ 3,4 ] Nanoparticulate drug formula-
tions, exploiting this feature of the tumor microenvironment, 
can be used to deliver chemotherapeutic agents to tumor target 
sites thereby increasing the therapeutic effect while minimizing 
systemic toxicities. [ 5 ] When selecting a delivery system a major 
consideration is controlled release of the drug to the target site 
at a therapeutically optimal rate. [ 1,6 ] 
 Human ferritin is an ideal drug delivery carrier due to the 
nanoscale structure, and biocompatible, biodegradable, stable, 
nontoxic properties. [ 2,7,8 ] Ferritin consists of an apoferritin (AFt) 
protein cage and an iron core, and prevents accumulation of 
toxic levels of free iron in cells. AFt is composed of 24 subunits 
arranged into a 12 nm diameter cage with an internal 8 nm 
cavity. AFt is comprised of heavy (H) and light (L) chains which 
are highly homologous but functionally distinct. The AFt cage 
has 14 channels, each 3–4 Å in diameter, to allow exchange of 
cargo between the protein cage interior and exterior environ-
ments. Among the 14 channels, eight are hydrophilic and six 
are hydrophobic. [ 6,7,9 ] Also, the AFt cage can disassemble into 
subunits at low pH (<pH 4.0) allowing release of cargo, and 
reassemble at higher pH (>pH 5.0). [ 5 ] Ferritin circulates and 
binds to a variety of cell types, however, specifi c binding to cells 
has been seen only for H-ferritins. [ 10 ] Ferritin binding sites and 
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during mixing of the drug with the protein ( Figure  1 a). [ 28 ] 
Gefi tinib has low solubility in aqueous buffers [ 29 ] and was fi rst 
dissolved in dimethylsulfoxide (DMSO) and then diluted with 
phosphate buffered saline (PBS) at pH 7.2. This 1 × 10 −3 M 
aqueous solution of Gefi tinib was mixed with H-AFt. The lat-
eral dimensions of Gefi tinib are ≤0.3 nm, allowing Gefi tinib 
intake through six hydrophobic channels by diffusion. The 
resulting solution was exhaustively dialyzed and centrifuged at 
high speed to remove any unencapsulated Gefi tinib and any 
impurities. The encapsulation of Gefi tinib was confi rmed by 
UV spectrophotoscopy. Absorbance of Gefi tinib was analyzed 
at 250 nm and the encapsulation effi ciency (EE) was quantifi ed 
according to the Beer–Lambert law to be ≈55%. 
 Mass spectrometry measures the mass to charge ratio and 
can be used to determine the purity and the molar mass of 
the particles. [ 30 ] Matrix-enriched laser desorption ionization 
(MALDI) studies revealed high intensity peaks for H-AFt and 
Gefi tinib which indicates high abundance of the drug and the 
protein in the mixture corresponding to a H-AFt molecular 
weight ( M W ) of 24.71 kDa and Gefi tinib  M W of 442.6 Da, com-
parable to the expected values (S1, Supporting Information). 
Protein determination by Bradford assay revealed 1.25 mg 
H-AFt per ml—equivalent to 50.6 × 10 −6 M . UV spectrophotom-
etry determined a ratio of 605 × 10 −6 M Gefi tinib/50.6 × 10 −6 M 
H-AFt indicating >10 molecules of Gefi tinib per H-AFt cavity. 
Further evidence of Gefi tinib encapsulation within H-AFt was 
provided by fl ow cytometry analysis (Section S1, Supporting 
Information). 
 The stability and the structural integrity of H-AFt-encapsu-
lated-Gefi tinib were confi rmed by polyacrylamide gel electro-
phoresis (PAGE) and transmission electron microscopy (TEM). 
PAGE profi le of H-AFt-encapsulated-Gefi tinib revealed a band 
similar to that of H-AFt only, at  M W ≈ 24.7 kDa (Figure  1 b). 
This indicates that the AFt protein structure and charge remain 
unchanged after encapsulation of Gefi tinib. TEM images 
(Figure  1 c) show intact H-AFt shells with an outer diameter 
of 12.5 ± 0.46 nm, and confi rm that the H-AFt-encapsulated-
Gefi tinib retains the spherical shape and the size expected for 
H-AFt. The electron density of Gefi tinib molecules is similar to 
that of H-AFt, hence there was insuffi cient contrast to resolve 
encapsulated Gefi tinib in TEM. 
 In vitro effects of H-AFt-encapsulated-Gefi tinib were assessed 
using the HER2 overexpressing SKBR3 cell line that expresses 
low levels of EGFR. As a negative control MDA-MB-231 cell 
line was used which does not express HER2 but expresses high 
levels of EGFR. [ 24 ] 
 Cellular internalization of H-AFt-encapsulated-Gefi tinib 
was observed by confocal microscopy and compared to that 
of Gefi tinib. SKBR3 and MDA-MB-231 cells were treated with 
H-AFt-encapsulated-Gefi tinib, Gefi tinib, and H-AFt (5 × 10 −6 M ) 
for 24 h ( Figure  2 ; Section S2, Supporting Information). The 
fl uorescence of Gefi tinib is environmentally sensitive: peak 
excitation and emission depends upon environment polarity 
and is intense in nonpolar solvents. [ 31 ] This property has 
allowed cellular uptake and distribution studies to be per-
formed. Intracellular Gefi tinib was evident from the bright fl uo-
rescence observed within the cytoplasm of SKBR3 cells treated 
with H-AFt-encapsulated-Gefi tinib. Cytoplasmic Gefi tinib fl uo-
rescence was punctuate consistent with localization in acidic 
lysosomes and endosomes within these cells. [ 31 ] SKBR3 cells 
treated with H-AFt alone appeared to be identical to control 
cells and did not show fl uorescence. Also MDA-MB-231 cells 
treated with H-AFt-encapsulated-Gefi tinib did not show bright 
fl uorescence compared to MDA-MB-231 cells treated with 
Gefi tinib indicating uptake suppression. 
 The cellular uptake of H-AFt-encapsulated-Gefi tinib was 
quantifi ed using fl ow cytometry. SKBR3 and MDA-MB-231 cells 
were treated with H-AFt-encapsulated-Gefi tinib or Gefi tinib 
(5 × 10 −6 M ) for 24 h and compared to control. Mean fl uores-
cence was used as a measure of Gefi tinib uptake by the cells 
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 Table 1.  Effect of Gefi tinib, H-AFt-encapsulated-Gefi tinib, and H-AFt on growth of SKBR3 and MDA-MB-231 cells. It should be noted that the GI 50 
values for H-AFt-encapsulated-Gefi tinib refer to encapsulated Gefi tinib concentration; the amount of Gefi tinib encapsulated per H-AFt cage impacts 
material potency and merits further detailed studies. 
 Mean GI 50 value ± SE [µ M] 
 Gefi tinib H-AFt-encapsulated-Gefi tinib H-AFt
Cell line 72 h 120 h 72 h 120 h 72 h 120 h
SKBR3 0.94 ± 0.49 1.66 ± 0.79 1.44 ± 0.49 0.52 ± 0.17 4.84 ± 3.43 5.50 ± 3.81
MDA-MB-231 21.80 ± 0.52 19.56 ± 0.64 >25 >25 16.47 ± 0.98 19.85 ± 0.15
 Figure 1.  a) Schematic representation of preparation of H-AFt-encapsu-
lated Gefi tinib encapsulated NPs. b) PAGE- 1) Marker 2) H-AFt 3) H-AFt-
encapsulated-Gefi tinib. c) TEM Images of H-AFt-encapsulated Gefi tinib 
confi rming the size of the NPs. d) Mean fl uorescence uptake by SKBR3 
and MDA-MB-231 cells using fl ow cytometry. Mean and SD of 3 inde-
pendent trials ( n = 2 per trial).
© 2015 The Authors. Published by  WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com2818
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(Figure  1 d). Signifi cant uptake by SKBR3 and MDA-MB-231 
cells were measured for Gefi tinib. Uptake of H-AFt-encapsu-
lated-Gefi tinib by SKBR3 cells was also signifi cant; however 
uptake of H-AFt-encapsulated-Gefi tinib by MDA-MB-231 cells 
was not signifi cant compared to control. Thus, qualitative 
observations of confocal microscopy were corroborated by fl ow 
cytometry analyses, and demonstrate successful internaliza-
tion of H-AFt-encapsulated-Gefi tinib by HER2 overexpressing 
SKBR3 cells. 
 In order to study  in vitro antitumor activity of H-AFt-encapsu-
lated-Gefi tinib, cells were incubated with H-AFt-encapsulated-
Gefi tinib, Gefi tinib, and H-AFt for 72 h and growth inhibition 
was determined by MTT assay (Table  1 ;  Figure  3 a,b; Section S3, 
Supporting Information). Interestingly, the SKBR3 cell line 
was sensitive to both Gefi tinib (GI 50 = 0.94 ± 0.49 × 10 −6 M ) 
and H-AFt-encapsulated-Gefi tinib (GI 50 = 1.44 ± 0.49 × 10 −6 M ). 
However, the reduced potency of H-AFt-encapsulated-Gefi tinib 
compared to Gefi tinib alone implies that encapsulated Gefi tinib 
may require time to be released from the H-AFt cavity as it is 
processed by endosome and lysosome systems with a local pH 
gradually reducing. [ 31 ] Conversely the MDA-MB-231 cell line 
demonstrated signifi cantly reduced sensitivity to both Gefi tinib 
(GI 50 = 21.80 ± 0.52 × 10 −6 M ) and H-AFt-encapsulated-Gefi tinib 
(GI 50 > 25 × 10 −6 M ). 
 Although Gefi tinib is an EGFR tyrosine kinase inhibitor, no 
correlation was observed between EGFR expression and sensi-
tivity of cells. Gefi tinib activity requires a phosphorylated (active) 
form of EGFR whereas MDA-MB-231 cells express nonphospho-
rylated EGFR and hence are not sensitive to this drug. [ 24 ] On the 
other hand, cancer cells that express low levels of EGFR together 
with overexpression of HER2 are sensitive to this drug and indeed, 
high sensitivity of SKBR3 cells to Gefi tinib was observed. [ 24,25 ] 
HER2 remains the preferred dimerization partner of other ErbB 
receptors. Although both homo- and hetero-dimerization activate 
the EGFR network, heterodimers are found to be more potently 
mitogenic and HER2 heterodimers generate the strongest biolog-
ical activity compared to other heterodimers. [ 20,24,32 ] 
 TfR1 is associated with uptake of H-AFt and is more highly 
expressed in cancer cells compared to normal human cells. [ 12 ] 
It has been found that the expression of TfR1 correlates with 
tumor stage or cancer progression. [ 4 ] Iron is required by many 
cellular processes such as metabolism and DNA synthesis. 
TfR1 resides on cell membranes and imports cargo by receptor-
mediated endocytosis via clathrin-coated pits. [ 4,8 ] Both SKBR3 
and MDA-MB-231 cells possess high levels of TfR1 [ 33 ] which 
would assist cellular uptake of H-AFt-encapsulated-Gefi tinib. [ 34 ] 
The greater SKBR3 growth inhibition by H-AFt compared 
to MDA-MB-231 implies greater sequestration of H-AFt by 
SKBR3 cells. Indeed, it has been shown previously that ferritin 
was not taken up by MDA-MB-231 cells. [ 35 ] In this study, the 
enhanced activity of H-AFt-encapsulated-Gefi tinib in HER2 
overexpressing cells is also a consequence of Gefi tinib inhibi-
tion of kinase activity, and therefore EGFR signaling triggered 
by HER2-EGFR dimerization. 
 To determine whether a longer exposure time to encapsulated 
drug would be more effective in cells, MTT assays were per-
formed following 120 h treatment (Table  1 , Figure  3 c,d). Again 
the SKBR3 cell line showed greater sensitivity to H-AFt alone 
compared to MDA-MB-231 cells. Interestingly the GI 50 value 
for H-AFt-encapsulated-Gefi tinib (0.52 ± 0.17 × 10 −6 M ) against 
the SKBR3 cell line was lower compared to the 72 h assay 
(GI 50 = 1.44 ± 0.49 × 10 −6 M ) and it was also lower (≈3-fold) than 
that of Gefi tinib after 120 h exposure (GI 50 = 1.66 ± 0.79 × 10 −6 M ). 
No signifi cant difference was found between the GI 50 values 
of Gefi tinib alone at 72 and 120 h. It should be noted that at 
H-AFt-encapsulated-Gefi tinib GI 50 values of 1.44 × 10 −6 and 
0.52 × 10 −6 M , equivalent concentrations of AFt were 0.11 × 10 −6 
and 0.04 × 10 −6 M respectively, concentrations which negligibly 
impact SKBR3 cellular proliferation. Consistent with results 
following 72 h exposure, after 120 h exposure, the MDA-MB-
231 cell line did not show sensitivity to H-AFt-encapsulated-
Gefi tinib, GI 50 > 25 × 10 −6 M (equivalent to 2.1 × 10 −6 M AFt). 
 These results demonstrate that drug encapsulation enhances 
Gefi tinib activity in SKBR3 cells and support the hypothesis 
that the H-AFt cage allows controlled release of drug molecules. 
 Tumor microenvironments exhibit lower extracellular pH 
than normal tissues while the intracellular pH of cells within 
Adv. Healthcare Mater. 2015, 4, 2816–2821
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 Figure 2.  Confocal microscopy images of SKBR3 cells demonstrating 
cellular uptake of Gefi tinib after 24 h exposure of cells to: a) control, 
b) H-AFt, c) Gefi tinib, d) H-AFt-encapsulated-Gefi tinib. Representative 
images of 3 independent trials are shown ( n = 2 per trial).
© 2015 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com 2819
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normal and tumor cells is similar. [ 5 ] The overall pH range 
within a tumor environment is 6.5–7.2 where as normal 
cells possess a pH range of 7.2–7.4, allowing pH controlled 
release. [ 36 ] Further, the pH-dependent release of cargo could 
offer additional advantage for applications in stomach can-
cers, where an acidic environment would enhance drug release 
from the AFt cavity. Hence, it was examined whether a more 
acidic  in vitro environment would promote effective release of 
Gefi tinib from its H-AFt cage. The investigations indicated that 
SKBR3 cells were unable to withstand pH < 7.0 environments 
for more than 72 h. However, at pH = 7.0, H-AFt-encapsulated-
Gefi tinib inhibited SKBR3 cell growth in a dose-dependent 
manner following 72 h exposure (GI 50 = 0.44 ± 0.16 × 10 −6 M ), 
exhibiting >3-fold enhanced potency, compared to pH 7.5. 
Clonogenic assays were performed to determine whether 
individual SKBR3 cells were able to survive challenge with 
Gefi tinib or H-AFt-encapsulated-Gefi tinib and subsequently 
form progeny colonies, indicative of tumor repopulation. [ 37 ] 
After 24 h exposure to agents followed by 13 d incubation 
with medium alone, H-AFt-encapsulated-Gefi tinib demon-
strated lower potency than Gefi tinib ( Figure  4 ). The survival 
fraction (SF) of cells treated with Gefi tinib was 50.7% ± 1.5% 
(1 × 10 −6 M ) and 3.5% ± 1.0% (5 × 10 −6 M ) compared to control 
whereas SF of cells treated with H-AFt-encapsulated-Gefi tinib 
was 71.8% ± 0.5% (1 × 10 −6 M ) and 34.4% ± 5.2% (5 × 10 −6 M ). 
However, following 14 d continuous exposure to both agents, 
no colonies could be detected. These results endorse the 
premise of sustained drug release from H-AFt as an effi cient 
drug delivery system. 
 Release of Gefi tinib from H-AFt into buffer was examined 
at pH 2, 4, and 7.5 over a period of 24 h by analyzing both the 
buffer and the solution retained within the dialysis bags. UV 
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 Figure 4.  a) Photographs of SKBR3 colonies following treatment of cells 
with 5 × 10 −6 M H-AFt-encapsulated-Gefi tinib. b) Effect of Gefi tinib and 
H-AFt-encapsulated-Gefi tinib treatment on SKBR3 colony formation. 
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H-AFt. At pH 2 the AFt cage completely disassembles, at pH 
4 the AFt cage swells, separating the protein subunits and at 
pH 7.5 the AFt cage retains its assembled structure. [ 5 ] Rapid, 
cumulative diffusion of Gefi tinib alone was observed at pH 7.5, 
reaching a plateau at 6 h. In comparison, at pH 2, 4, and 7.5, 
detection of Gefi tinib released from H-AFt-encapsulated-Gefi -
tinib indicates a slower cumulative release profi le; progressively 
reduced drug was released from the AFt cage as pH increases 
(Section S4, Supporting Information). The most rapid cumula-
tive release profi le was observed at pH 2, consistent with the 
AFt cage disassembling and allowing Gefi tinib release. 
 Analysis of residual buffer by fl ow cytometry (Section S4, 
Supporting Information) revealed only two negative popula-
tions at pH 2 and 4, exposing very low total fl uorescence in 
the histograms relative to control. This implies that negli-
gible amounts of Gefi tinib were retained in the dialysis bags; 
after 24 h. However at pH 7.5, a small population positive for 
fl uorescence was observed; indicating that some drug mol-
ecules remained encapsulated, confi rming sustained release of 
Gefi tinib from H-AFt at physiological pH levels. [ 36 ] 
 The  in vitro results indicate that encapsulation of Gefi tinib 
within an H-AFt cage could provide a facile route to targeted 
drug delivery and release in vivo. Recognition of H-AFt by 
TfR1 of cancer cells allows encapsulated cargo to be selectively 
internalized into cancer cells via TfR1 mediated endocytosis [ 3,4 ] 
and has successfully been utilized for targeted delivery of, e.g., 
MRI imaging agents. Although angiogenesis is enhanced in 
cancers [ 38 ] suggesting potential competition between endog-
enous ferritins and H-AFt uptake, a recent study demonstrated 
successful delivery of doxorubicin encapsulated in H-AFt to 
tumor sites and in vivo effi cacy. [ 18 ] Thus, we envisage that the 
observed selective targeting and enhanced effi cacy could be 
translated  in vivo and merits further detailed studies. 
 In conclusion, successful encapsulation of Gefi tinib within 
the H-AFt cavity, sustained release of cargo, and subsequent 
antitumor activity selectively in HER2 overexpressing breast 
carcinoma cells are shown. Utilizing the fl uorescent property 
of Gefi tinib, it was able to confi rm intracellular localization 
of H-AFt-encapsulated-Gefi tinib in SKBR3 cells. Potent, dose-
dependent growth inhibition of cancer cells sensitive to EGFR 
inhibition was achieved and clonogenic assays further provided 
evidence of sustained Gefi tinib release and signifi cant in vitro 
anticancer activity of H-AFt-encapsulated-Gefi tinib. H-AFt 
encapsulation can reduce off target toxicities of Gefi tinib and 
diminish drug deposition in normal tissues. AFt encapsulation 
enhances the therapeutic effi cacy of Gefi tinib through passive 
targeted delivery and sustained release to tumor sites which 
demonstrates a successful nanoscale drug delivery system. 
 Experimental Section 
 Preparation and Characterization of H-AFt-Encapsulated-Gefi tinib : 
Gefi tinib (Cayman Chemical USA) was dissolved in DMSO:PBS (1:1 at 
pH 7.2) at a concentration of 1 × 10 −3 M . 160 × 10 −6 M synthetic human 
H-AFt expressed in  E. coli was provided by Prof. N. R. Thomas. There 
were additional His- and Avidin-tags and also linker sequences in the 
provided H-AFt. This increases the size of H-AFt from 21 to ≈24 kDa. 
H-AFt was added to Gefi tinib solution with 40-fold excess of drug, and 
was stirred overnight at 4 °C. The unencapsulated Gefi tinib was removed 
by dialysis in 20 × 10 −3 M Tris (pH 8.0) using a dialysis membrane (cut-off 
8 kDa) for 48 h at 4 °C. Any impurities were removed by centrifugation 
(13 000 rpm, 12 min, 4 °C). The protein concentration of H-AFt was 
determined by Bradford assay. [ 39 ] The morphology was examined by 
TEM (JEOL 2100F at 200 kV). For sodium dodecyl sulfate (SDS)-PAGE, 
following denaturation ( T = 95 °C for 5 min), 10 µL of H-AFt, H-AFt-
encapsulated-Gefi tinib and 5 µL of molecular marker (Thermo Scientifi c) 
were loaded onto a 4% stacking gel and resolved in a 12% resolving gel; 
samples were separated at 100 V for 2.5 h. The gel was stained overnight 
with 0.5% coomassie blue, followed by destaining with 50% methanol 
and 10% acetic acid, and imaged in an UVP BioDoc-It system. 
 Determining Encapsulation Effi ciency (EE) : Absorbance of serial 
dilutions of Gefi tinib (from 250 × 10 −6 to 0.5 × 10 −6 M in DMSO) at 250 nm 
was analyzed using Perkin-Elmer Lambda 25 UV/vis Spectrometer and 
WinLab ver. 6.0.4.0738 and the Beer–Lambert law was used to quantify 
the encapsulated drug. The EE was estimated as a ratio between the 
concentration of the encapsulated drug and that used in synthesis. 
 Confi rmation of Encapsulation of Gefi tinib in H-AFt : H-AFt-
encapsulated-Gefi tinib solution was analyzed using an Astrios EQ fl ow 
cytometer (Beckman Coulter, Summit 6.2.3.1561) equipped with 488 
and 355 nm lasers. Fluorescence emission was collected using a 405/30 
band-pass fi lter. 
 Mass Spectrometry : For MALDI, H-AFt-encapsulated-Gefi tinib (10 µL) 
was mixed with sinapic acid and 0.5 µL of the resulting solution was 
loaded onto a MALDI target sample plate. The plate was left to air dry 
for 5 min and was analyzed on the Bruker Ultrafl ex III spectrometer. 
 Cell Lines and Cell Culture : SKBR3 and MDA-MB-231 breast cancer cell 
lines (European Collection of Cell Cultures) were maintained in RPMI 
1640 medium supplemented with 10% fetal bovine serum (FBS) at 
37 °C in a humidifi ed atmosphere containing 5% CO 2 . 
 MTT Assay : Cells were seeded in 96 well plates (2.5 × 10 3 per well) for 
24 h before treatment with Gefi tinib, H-AFt-encapsulated-Gefi tinib, and 
H-AFt. Following 72 h or 120 h exposure, MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide; 400 µg mL −1 ) was added and 
plates were incubated for 2.5 h. Well supernatants were aspirated and 
formazan solubilized with 150 µL 100% DMSO. Absorbance at 550 nm 
was read on Perkin–Elmer plate reader. 1  M HCl was introduced into 
medium dropwise for MTT assays at pH 7.0. 
 Clonogenic Assay : SKBR3 cells (250 per well) were seeded into 6 well 
plates and allowed for 24 h to attach. Following 24 h treatment with 
Gefi tinib and H-AFt-encapsulated-Gefi tinib (1 × 10 −6 and 5 × 10 −6 M ), in 
half of the wells test agent was replaced with 2 mL of fresh medium. 
Cells in the remaining wells were exposed to test agents for 14 d. 
Experiments were terminated when colonies of ≥ 50 cells were formed 
in control wells. Colonies were washed (PBS), fi xed (methanol; 15 min), 
stained (0.5% methylene blue; 15 min) and counted. SF were calculated: 
SF = Plating effi ciency of treated sample/Plating effi ciency of control 
× 100%. [ 37 ] 
 Release of Gefi tinib from H-AFt : Dialysis bags (cut-off 8 kDa) 
containing H-AFt-encapsulated-Gefi tinib (100 × 10 −6 M ) and Gefi tinib 
(100 × 10 −6 M ) diluted in 20 × 10 −3 M Tris buffer (900 µL) were placed 
in separate beakers containing 20 × 10 −3 M Tris buffer at pH 2, 4 or 7.5 
at 37 °C, 5% CO 2 . Released Gefi tinib was quantifi ed after 2, 6, 12, and 
24 h by UV spectrophotometry at 250 nm. Gefi tinib in the residual buffer 
within the dialysis bags was detected by Astrios EQ fl ow cytometry. 
 Cellular Uptake Studies : For confocal microscopy, SKBR3 and MDA-
MB-231 (2 × 10 4 ) cells were seeded into 8 well coverslips and allowed 
to attach overnight. Following 24 h exposures with Gefi tinib or H-AFt-
encapsulated-Gefi tinib (5 × 10 −6 M ), live imaging of cells was carried 
out using a Zeiss LSM 510 fl uorescence microscope equipped with 
a UV laser of 351 nm excitation and LP385 emission fi lter. For fl ow 
cytometry studies, SKBR3 and MDA-MB-231 cells (2.5 × 10 5 ) were 
seeded in 6 well plates and allowed to attach overnight before 24 h 
exposure to Gefi tinib or H-AFt-encapsulated-Gefi tinib (5 × 10 −6 M ). 
Cells were washed and collected into FACS tubes. Using an Astrios EQ 
fl ow cytometer, 20 000 events were acquired and Gefi tinib fl uorescence 
was collected. 
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 Statistical Analyses : All experiments were repeated ≥3 times and 
results are presented as means ± SD (Standard Deviation) or ± SE 
(Standard Error). Signifi cant differences were defi ned as  P < 0.05. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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